Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Avidity Biosciences (RNA) has granted equity-based inducement awards to 16 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The awards include 71,000 non-qualified stock options with an exercise price of $31.64 per share and 35,000 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. All awards are subject to continued employment and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for joining the company.
Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The company's management will engage in a fireside chat scheduled for Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. ET. Investors can access the live webcast and replay of the presentation through Avidity's investor relations website.
Avidity Biosciences (Nasdaq: RNA) has announced new equity grants under its 2022 Employment Inducement Incentive Award Plan. The company granted 263,000 non-qualified stock options and 131,450 restricted stock units (RSUs) to 33 new non-executive employees as employment inducements, complying with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $26.66 per share, matching Avidity's closing price on Nasdaq Global Market on April 17, 2025. The options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest in four equal annual installments. Both grants require continued employment for vesting.
Avidity Biosciences (RNA) has achieved a significant milestone as its drug delpacibart etedesiran (del-desiran) received Orphan Drug designation in Japan for treating myotonic dystrophy type 1 (DM1). This marks the first DM1 treatment to receive this designation in Japan.
Del-desiran, designed to target the root cause of DM1 (a progressive and often fatal neuromuscular disease), has already secured multiple regulatory designations including Breakthrough Therapy, Orphan Drug, and Fast Track from the FDA, along with Orphan designation from the EMA.
The company reports promising results from the MARINA and MARINA-OLE studies, showing favorable long-term safety, disease progression reversal, and sustained clinical improvements. Avidity expects to complete enrollment in the Phase 3 HARBOR trial by mid-2025, with marketing applications planned for submission starting 2026 in the U.S., EU, and Japan.
Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 3:00 p.m. ET.
Investors and interested parties can access the live webcast and replay of the presentation through the 'Events and Presentations' section on Avidity's investor relations website at aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA) has completed enrollment of 51 participants in the biomarker cohort of its Phase 1/2 FORTITUDE™ trial for delpacibart braxlosiran (del-brax), targeting facioscapulohumeral muscular dystrophy (FSHD). The company aims to be first to market with an approved FSHD treatment.
Del-brax, at 2 mg/kg dosage, has shown promising results including:
- Unprecedented reductions in DUX4-regulated genes
- Significant decreases in novel circulating biomarker and creatine kinase
- Trends of functional improvement
- Favorable safety and tolerability
Key Q2 2025 milestones include:
- Updates on potential U.S. accelerated approval pathway
- Global Phase 3 trial design alignment and initiation
- Topline data from FORTITUDE dose escalation cohorts
Avidity Biosciences (Nasdaq: RNA) has granted equity awards to 16 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The grants, announced on March 21, 2025, include:
- Non-qualified stock options to purchase 101,200 common shares at $30.83 per share
- 50,900 restricted stock units (RSUs)
The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over 36 months. RSUs will vest in four equal annual installments. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4) and are subject to continued employment with Avidity.
Avidity Biosciences (Nasdaq: RNA) announced positive topline data from its Phase 1/2 EXPLORE44® trial for del-zota in treating Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44). The trial demonstrated statistically significant improvements across key biomarkers:
- Approximately 40% increase in exon 44 skipping
- 25% of normal dystrophin production with total dystrophin restored up to 58% of normal
- Over 80% reduction in creatine kinase levels compared to baseline
- Favorable safety and tolerability across dose cohorts
Based on consistent results between dosing groups, Avidity selected 5 mg/kg every six weeks for their Biologics License Application (BLA) submission, planned for year-end 2025. The drug has received FDA's Orphan, Rare Pediatric Disease, and Fast Track designations, as well as EMA's Orphan designation.